A Multicentric, Randomized, Double-blind, Parallel Group, Two Arm, Comparative, Phase III Clinical Study to Evaluate the Efficacy, Safety and Tolerability of Etofenamate 10 percent w/w gel versus Diclofenac 1.16 percent w/w gel in patients with musculoskeletal pain

Musculoskeletal pain is prevalent worldwide and greatly impacts the quality of life, social participation and economic burden. National & International Guidelines, Recommend to consider  Topical NSAIDs and/or Paracetamol as first-line therapy ahead of Oral NSAIDs, COX-2 inhibitors or Opioids. Etofenamate is a Non-Steroidal Anti-Inflammatory Drug (NSAID). Etofenamate is not yet approved in India and this study is conducted to Evaluate the Efficacy, Safety and Tolerability of Etofenamate 10 % w/w gel versus Diclofenac 1.16 % w/w gel in patients with musculoskeletal pain